What is Erste Group Bank’s Estimate for BMY FY2026 Earnings?

Bristol Myers Squibb Company (NYSE:BMY) – Equities research analysts at Erste Group Bank increased their FY2026 earnings estimates for Bristol Myers Squibb in a research report issued to clients and investors on Wednesday, February 18th. Erste Group Bank analyst H. Engel now anticipates that the biopharmaceutical company will earn $6.25 per share for the year, up from their previous forecast of $5.99. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Erste Group Bank also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $5.92 EPS.

Several other analysts have also commented on the stock. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Bank of America raised Bristol Myers Squibb from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Leerink Partners lifted their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Finally, Truist Financial set a $65.00 price objective on Bristol Myers Squibb in a report on Wednesday, December 3rd. Nine research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $60.75.

Bristol Myers Squibb Price Performance

Shares of NYSE BMY opened at $61.24 on Monday. The firm has a 50-day moving average of $56.36 and a two-hundred day moving average of $50.15. The company has a market capitalization of $124.72 billion, a price-to-earnings ratio of 17.75, a PEG ratio of 0.17 and a beta of 0.29. The company has a current ratio of 1.26, a quick ratio of 1.14 and a debt-to-equity ratio of 2.32. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The firm’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS.

Bristol Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s payout ratio is presently 73.04%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several institutional investors and hedge funds have recently modified their holdings of BMY. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb in the 4th quarter worth about $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at approximately $25,000. Physician Wealth Advisors Inc. increased its holdings in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 202 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 313 shares in the last quarter. Finally, EQ Wealth Advisors LLC acquired a new stake in Bristol Myers Squibb in the fourth quarter valued at approximately $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA accepted BMY’s New Drug Application for iberdomide in relapsed/refractory multiple myeloma and granted Breakthrough Therapy Designation and Priority Review — a clear near‑term valuation catalyst if review goes well; this increases the chance of a meaningful label and revenue contribution in a hard‑to‑treat indication. FDA Review Of Iberdomide Puts Fresh Focus On Bristol Myers Valuation
• Positive Sentiment: Barclays initiated BMY with an Overweight rating and $75 price target, citing pipeline potential despite an approaching patent‑cliff — analyst initiation can attract investors and support upward momentum, especially combined with regulatory and clinical wins. Barclays Initiates Bristol Myers (BMY) with Overweight Rating on Pipeline Potential
• Positive Sentiment: BMY reported positive top‑line registrational Phase 2 results for luspatercept in adults with alpha (α)-thalassemia — another pipeline expansion that could underpin future revenue and offset losses from older franchises over time. Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
• Neutral Sentiment: Bristol Myers will present at the TD Cowen 46th Annual Health Care Conference — a routine investor event where management may provide more color on pipeline timing and commercial expectations; useful for updates but not an immediate guarantee of material news. Bristol-Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
• Neutral Sentiment: Mention in broader market pieces (large‑cap stock roundups and sector previews) keeps BMY on investors’ radars but does not add a company‑specific catalyst; monitor analyst notes (e.g., Erste/Erste Group coverage) for changes to consensus estimates. What is Erste Group Bank’s Estimate for BMY FY2026 Earnings?

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.